Abstract
BackgroundAbatacept (CTLA-4Ig) inhibits the binding of CD28 to the B7 ligands CD80/CD86 on antigen presenting cells (APC) and thereby effector T cell activation. Costimulatory molecules can also be expressed on...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have